Structure Therapeutics Inc.
GPCR
$19.61
$0.241.24%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 32.74% | 37.41% | 51.24% | 77.81% | 98.80% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 79.36% | 58.52% | 53.96% | 67.77% | 71.80% |
Operating Income | -79.36% | -58.52% | -53.96% | -67.77% | -71.80% |
Income Before Tax | -78.02% | -46.70% | -36.73% | -44.46% | -53.04% |
Income Tax Expenses | 165.71% | 57.92% | 31.36% | -137.50% | 386.11% |
Earnings from Continuing Operations | -78.17% | -46.73% | -36.72% | -43.59% | -53.23% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -78.17% | -46.73% | -36.72% | -43.59% | -53.23% |
EBIT | -79.36% | -58.52% | -53.96% | -67.77% | -71.80% |
EBITDA | -79.37% | -58.26% | -53.46% | -67.39% | -71.63% |
EPS Basic | -39.36% | -10.97% | 7.82% | 60.04% | 74.32% |
Normalized Basic EPS | -34.37% | -5.25% | 13.70% | 60.78% | 75.00% |
EPS Diluted | -39.36% | -10.97% | 7.82% | 60.04% | 74.32% |
Normalized Diluted EPS | -34.37% | -5.25% | 13.70% | 60.78% | 75.00% |
Average Basic Shares Outstanding | 27.02% | 30.58% | 43.42% | 92.20% | 162.72% |
Average Diluted Shares Outstanding | 27.02% | 30.58% | 43.42% | 92.20% | 162.72% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |